Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice by Moiola, Cristian Pablo et al.
 Published OnlineFirst May 19, 2014.Clin Cancer Res 
  
Cristian P Moiola, Paola De Luca, Florencia Zalazar, et al. 
  
fat diet fed mice.
Prostate tumor growth is impaired by CtBP1 depletion in high
  
Updated version
  
 10.1158/1078-0432.CCR-14-0322doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2014/06/03/1078-0432.CCR-14-0322.DC1.html
Access the most recent supplemental material at:
  
Manuscript
Author
edited. 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been
  
  
  
  
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
  
Permissions
  
.permissions@aacr.orgDepartment at
To request permission to re-use all or part of this article, contact the AACR Publications
Research. 
on June 18, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 19, 2014; DOI: 10.1158/1078-0432.CCR-14-0322 
1 
 
Prostate tumor growth is impaired by CtBP1 depletion in high fat diet fed mice. 
 
Cristian P. Moiola1,2; Paola De Luca1,2; Florencia Zalazar1,2; Javier Cotignola2; Santiago A. Rodríguez-Seguí3; 
Kevin Gardner4; Roberto Meiss5; Pablo Vallecorsa5; Omar Pignataro6; Osvaldo Mazza7; Elba S. Vazquez2 & 
Adriana De Siervi1,2†. 
1Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, IBYME-CONICET. Buenos Aires, 
Argentina.  
2Laboratorio de Inflamación y Cáncer, Departamento de Química Biológica, Facultad de Ciencias Exactas 
y Naturales (FCEN), Universidad de Buenos Aires (UBA), IQUIBICEN - CONICET, Buenos Aires, Argentina. 
3Departamento de Fisiología, Biología Molecular y Celular, Facultad de Ciencias Exactas y Naturales 
(FCEN), Universidad de Buenos Aires (UBA),  and Instituto de Fisiología, Biología Molecular y 
Neurociencias (IFIBYNE), CONICET. Buenos Aires, Argentina. 
4Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of 
Health, Bethesda, USA. 
5Departamento de Patología, Instituto de Estudios Oncológicos, Academia Nacional de Medicina, Buenos 
Aires, Argentina. 
6Laboratorio de Endocrinología Molecular y Transducción de Señales, IBYME-CONICET. Departamento de 
Química Biológica, Facultad de Ciencias Exactas y Naturales (FCEN), Universidad de Buenos Aires (UBA), 
Buenos Aires, Argentina. 
7Hospital de Clínicas “José de San Martín”, Buenos Aires, Argentina. 
†Corresponding author: 
Adriana De Siervi, Laboratorio de Oncología Molecular y Nuevos Blancos Terapéuticos, IBYME-CONICET. 
Vuelta de Obligado 2490, Buenos Aires, Argentina. C1428ADN. Phone: +5411-4783-2869, ext. 206. Email: 
adrianadesiervi@gmail.com 
Running title: CtBP1 and high fat diet regulates PCa growth. 
Conflicts of Interest: No potential conflicts of interest were disclosed. 
Research. 
on June 18, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 19, 2014; DOI: 10.1158/1078-0432.CCR-14-0322 
2 
 
Statement of significance: 
Chronic high fat diet intake induces metabolic syndrome and modulates CtBP1 expression. We reveal a 
novel molecular link between high fat diet and prostate tumor growth. Our results suggest that 
metabolic syndrome-like diseases and CtBP1 expression cooperate to induce prostate tumor growth. 
Targeting of CtBP1 expression might be considered for PCa management and therapy in the subset of 
patients with metabolic syndrome. Our findings are highly relevant because CtBP1 pathway might help 
to identify new molecular candidates for better prediction of PCa progression in a set of patients with 
metabolic syndrome. 
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Abstract 
 
Purpose: Clinical and epidemiological data suggest that obesity is associated with more aggressive forms 
of prostate cancer (PCa), poor prognosis and increased mortality. C-terminal Binding Protein 1 (CtBP1) is 
a transcription repressor of tumor suppressor genes and is activated by NADH binding. High calorie 
intake decreases intracellular NAD+/NADH ratio. The aim of this work was to assess the effect of high fat 
diet (HFD) and CtBP1 expression modulation over prostate xenograft growth. 
Experimental design: We developed a metabolic syndrome-like disease in vivo model by feeding male 
nude mice with HFD during 16 weeks. Control diet (CD) fed animals were maintained at same 
conditions. Mice were inoculated with PC3 cells stable transfected with shCtBP1 or control plasmids. 
Genome-wide expression profiles and Gene Set Enrichment Analysis (GSEA) was performed from 
PC3.shCtBP1 versus PC3.pGIPZ HFD fed mice tumors. 
Results: No significant differences were observed in tumor growth on CD fed mice; however, we found 
that only 60 % of HFD fed mice inoculated with CtBP1 depleted cells developed a tumor. Moreover 
these tumors were significantly smaller than those generated by PC3.pGIPZ control xenografts. We 
found 823 genes differentially expressed in shCtBP1 tumors from HFD fed mice. GSEA from expression 
dataset showed that most of these genes correspond to cell adhesion, metabolic process and cell cycle. 
Conclusions: Metabolic syndrome-like diseases and CtBP1 expression cooperate to induce prostate 
tumor growth. Hence, targeting of CtBP1 expression might be considered for PCa management and 
therapy in the subset of patients with metabolic syndromes.  
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Introduction  
Prostate cancer (PCa) continues to be a major health care problem worldwide (1). Epidemiological 
studies indicate that elevated body mass index (BMI) correlates with elevated risk of PCa-specific 
mortality and biochemical recurrence (2). Due to the increase of overweight and obesity incidences 
throughout the world, the number of men at risk for developing PCa is also on the rise. There are several 
molecular mechanisms that physiologically link obesity to cancer risk; however, it remains a puzzle how 
exactly obesity activates the transformation pathways that result in cancer.  
Calorie excess intake impacts life span, the incidence of diseases and metabolic disorders through 
diverse mechanisms (3). For instance, nutrient excess influences NAD+/NADH ratio with the associated 
increase of reactive oxygen species (ROS) as a consequence of incomplete mitochondrial electron 
transfer during respiration. High ROS influences cell proliferation, differentiation and death, as these 
processes are intrinsically dependent upon the cellular redox status. In addition, ROS also contribute to 
increase the risk of malignant transformation by causing DNA damage (4). Calorie excess affects NAD+ 
availability, which in turn, modulates the activity of certain classes of mammalian proteins that utilize 
NAD+ or NADH as cofactors, ligands or substrates. Some of these molecules include: the Sirtuin family of 
Class III histone deacetylases, the PARP family of poly ADP ribosyl-transferases, and the C-terminal 
binding protein (CtBP) class of transcriptional repressors, which are involved in DNA damage response 
(4).  
CtBP1 was first identified as a cellular protein that binds to the carboxy terminus of E1A (5). It is more 
active as a dimer and its dimerization is promoted by NAD(H) binding (6). Hence, CtBP1 is assumed as 
both a sensor and an effector of cellular metabolic status due to its much higher affinity (>100-fold) for 
NADH compared to NAD+ (7). CtBP1 interacts with a broad range of transcription factors and represses 
transcription of several tumor suppressor genes such as E-cadherin, BRCA1, CDKN2A, Sirtuin 1 (SIRT1) 
and PTEN (6, 8-11). Therefore, since the discovery of CtBP1 several efforts were made to assess the 
involvement of CtBP1 in cancer development (12, 13).  
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Previously, Di et al showed that NAD+/NADH levels selectively regulate BRCA1 tumor suppressor gene 
(8). The release of CtBP1 from the BRCA1 promoter through estrogen induction or enhanced 
NAD+/NADH ratio leads to HDAC1 dismissal, elevated histone acetylation and increased BRCA1 
transcription, diminishing cancer risk (8). 
CtBP1-mediated transcriptional repression of E-cadherin seems to be regulated by the hypoxic 
environment in solid tumors with poor vascularization and high metabolic activity. A hypoxic condition 
that increases free NADH levels has been shown to enhance recruitment of CtBP1 to the E-cadherin 
promoter inducing tumor cell motility. Hence, CtBP1 was suggested to participate in the epithelial to 
mesenchymal transition (EMT) (6).  
In summary, literature fosters a strong role for CtBP1 as a negative regulator of several important tumor 
suppressors. This function suggests that CtBP1 might be crucial in tumor initiation and progression. In 
addition, the regulation of CtBP1 by NAD+/NADH places this factor in the category of molecules that link 
transcription to cellular metabolism. Nevertheless, the importance of CtBP1 as a sensor of nuclear redox 
state in vivo has yet to be determined. Our hypothesis was that enhanced CtBP1 activity in prostate 
tissues with low NAD+/NADH ratios, as a consequence of high calorie intake, contributes to increase 
prostate tumor development. Here, we explored CtBP1 role in prostate malignant transformation. Using 
an in vivo model of reduced NAD+/NADH ratio, we investigated the effect of the high fat diet (HFD) on 
prostate tumor growth through CtBP1 modulation. We focused our studies in the molecular pathways 
regulated by CtBP1 and the interplay with sexual hormones in PCa.  
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Methods 
 
Cell culture, transfections and treatments.  
PC3 (ATCC: CRL-1435), 22Rv1 (ATCC: CRL-2505), LNCaP (ATCC: CRL-1740) and C4-2 (14) PCa cells were 
grown in RPMI 1640 (GIBCO, Grand Island, NY, USA) with 10% fetal bovine serum (FBS) in a 5% CO2 
humidified atmosphere at 37°C.  
PC3 stable cell line (PC3.CtBP1) was generated by transfecting with pcDNA3.CtBP1 plasmid (15 μg, 
Origene) and lipofectamine 2000 (Invitrogen, Sao Pablo, Brazil) as previously described (15). PC3 CtBP1 
depleted cells (PC3.shCtBP1) lentiviral infection was performed as described in Supplemental Methods.  
PC3 cells were exposed to testosterone undecanoate (10 µM) or DMSO as vehicle in phenol red free 
RPMI 1640 medium (GIBCO) supplemented with 10% charcoaled FBS. Letrozole (Femara®-Novartis) was 
prepared in ethanol and PC3 cells were exposed for 1h (5 µM) previously to testosterone stimulation 
and incubated for 24 h. PC3 cells were transfected with lipofectamine 2000 and 1 µg of AR5 vector 
(gently gifted by Dr. G.  Jenster, Erasmus University Rotterdam, Netherlands). 
 
Chromatin immunoprecipitation (ChIP), RT-qPCR, Western blot and IHC. 
ChIP, RT-qPCR, WB and IHC were performed as described in Supplemental Methods (15-17). 
 
Focus formation and clonogenic assays.  
NIH3T3 cells were transfected with 5 µg pcDNA3.CtBP1 or control (pcDNA3.β-Gal) plasmids by calcium-
phosphate method as previously described (18). For clonogenic assays, 103 cells were seeded in a 100 
mm plate and incubated for 2 weeks. In both methods, cells were methanol-fixed and stained with 
crystal violet. Foci number and area were quantified using GelPro Analizer v4.0 software. Photographs 
were acquired with Phosphorimager (Fuji Photo Film Co. Ltd.). 
 
PC3-high fat xenograft model. 
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All animal experiments followed the institutional guidelines for animal welfare. Four week old athymic 
male Swiss nu/nu mice were fed for 16 weeks with control diet (CD) (n=18) or HFD (n=18). Chow food 
was supplemented with bovine fat in a 2:1 proportion (w/w) to generate HFD. CD and HFD had 3 kcal or 
5 kcal per gram of food, respectively. After 12 weeks of diet, each CD and HFD fed mice group were 
randomly divided and s.c. injected with PC3.pGIPZ or PC3.shCtBP1 cells (4.8 x 106). Body weight was 
determined three times a week. Tumor size was measured for 4 to 6 weeks and tumor volume was 
calculated as described (19). At necropsy, blood was drawn from all mice by direct heart puncture; 
serum was separated and tumors were excised. Tissues were formalin fixed and paraffin-embedded. 
Histopathology and IHC studies were performed in 5 µm tissue sections using  hematoxylin and eosin 
(H&E) or specific antibodies: anti-CtBP1 (BD Biosciences); anti-BRCA1 (ARP33338_P050, Aviva System 
Biology, San Diego, CA, USA), anti-E-cadherin (Clone HECD-1, Zymed Laboratories Inc, San Francisco, CA, 
USA); and anti-Cyclin D1 (H295, Santa Cruz Biotechnologies).   
Serum cholesterol, triglycerides, glycemia, NAD+/NADH levels, testosterone and estradiol 
determinations were performed as described in Supplemental Methods. 
 
Microarrays 
Microarrays were performed as described in Supplemental Methods. (20) 
 
Statistical Analysis 
All results are given as mean ± standard deviation of three independent experiments. Students´ t tests 
were used to ascertain statistical significance with a threshold of P < 0.05. For in vivo experiments two-
way ANOVA followed by Dunnett test were performed. Shapiro-Wilk and Levene test were used to test 
normality and homogeneity of variances. * p<0.05; ** p<0.01; *** p<0.001. 
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Results 
 
CtBP1 is overexpressed in human prostate tumors  
We analyzed CtBP1 expression on a small group of 20 radical prostatectomies specimens and we found 
that normal, benign and carcinomatous epitheliums showed different positive CtBP1 immunoreactivity 
patterns (Fig. 1A). Normal glands columnar epithelia cells and some basal cells showed a mild positive 
nuclear stain (Fig. 1A), while in benign prostatic hyperplasia, the columnar epithelium showed a 
moderate positive nuclear immunostain (Fig. 1A). Remarkably, all the cells in the epithelia of the 
carcinomatous glands showed intense nuclear and moderate cytoplasmatic immunostaining (Fig. 1A).  
In accordance with these findings showing that CtBP1 expression is increased in human PCa samples, 
recently, Wang et al. (12) observed CtBP1 overexpression and mislocalization in human metastatic PCa.  
 
CtBP1 increases transformation and proliferation in vitro 
To investigate whether CtBP1 induces transformation in vitro, we performed the focus formation assay 
transfecting NIH 3T3 cells with pcDNA3.CtBP1 or control vectors. We found that CtBP1 transfected cells 
showed larger and higher number of foci compared to control (Fig. S1A).  
Next, we determined CtBP1 expression in PCa cell lines (Fig. 1B). We found that androgen sensitive 
LNCaP cells showed higher CtBP1 expression compared to the other PCa cells lines. Notably, androgen-
insensitive PC3 cells showed five times lower CtBP1 expression than LNCaP cells (Fig. 1B). We generated 
stable transfected PC3 cells with enhanced (PC3.CtBP1) or depleted (PC3.shCtBP1) CtBP1 expression, as 
confirmed by WB and RT-qPCR compared to PC3.pGIPZ control cells (Fig. 1C and S1B). 
In order to determine CtBP1 role on cell proliferation, we assessed stable transfected PC3 cells 
clonogenic capacity. PC3.shCtBP1 cells showed significantly lower colony number compared to control 
(Fig. 1D). On the other hand, CtBP1 overexpression increased not only the colony number but also the 
colony area (Fig. 1D). Altogether, these results indicate that CtBP1 induces transformation of NIH 3T3 
cells and proliferation of prostate tumor PC3 cells in vitro.  
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HFD induces metabolic syndrome-like disease in nude mice 
Based on high NADH levels induce CtBP1 dimerization and activation (7), we investigated whether HFD 
influences NAD+/NADH ratio and, in turn, tumor growth using a murine xenograft experimental model. 
Males nu/nu mice fed with HFD or CD during 12 weeks were s.c. inoculated with PC3.pGIPZ or 
PC3.shCtBP1 stable cell lines. After 4 to 6 weeks from cell inoculation mice were sacrificed. Despite HFD 
fed mice showed a trend towards gaining body weight, no significant differences were detected among 
mice fed with HFD or CD along the experiment (Fig. 2A). Nevertheless, animals fed with HFD presented 
hypercholesterolemia at the end of the experiment (Fig. 2B), with no significant changes in serum 
triglycerides and glycemia compared to control mice (Fig. S2A-B).  
As a consequence of a prolonged HFD intake, animals developed a metabolic syndrome-like disease, 
evidenced by hormonal imbalance and kidney and liver histological architecture disorganization. We 
found significant decreased testosterone serum levels in HFD mice (Fig. 2C) with no changes in estradiol 
serum levels (Fig. S2C).  
Furthermore, kidneys from HFD fed mice showed glomeruli significantly enlarged by mesangial 
hypercellularity and edema at the epithelium of the collecting duct (Fig. S2D), while liver displayed 
altered architecture of hepatic lobules and a pronounced vacuolization of hepatic cells as a consequence 
of steatosis (Fig. S2E).   
 
CtBP1 depletion decreases tumor growth in HFD fed mice 
We assessed tumor growth in a xenograft model injected s.c. with PC3.shCtBP1 or PC3.pGIPZ cells. As 
shown in Fig. 3A, non-significant differences were observed in the tumor growth curves from 
PC3.shCtBP1 and PC3.pGIPZ cells in the CD group. Interestingly, in the HFD group, CtBP1 depleted PC3 
cells developed significantly smaller tumors than animals inoculated with PC3 control cells (Fig. 3B). In 
addition, we could not detect tumor growth in 40 % of mice injected with PC3.shCtBP1 cells and fed 
with a HFD while all the animals of the other 3 groups developed tumors. 
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Remarkably, tumors from HFD fed mice showed significantly reduced NAD+/NADH ratio which strongly 
support our hypothesis that HFD induces NADH levels (Fig. 3C). Moreover, estradiol levels in HFD 
xenografts were increased but no significant changes in intratumoral testosterone levels were observed 
(Fig. S3A-B).  
Histological characterization revealed that all tumors were poorly differentiated adenocarcinoma (Fig. 
3D). Moreover, CtBP1 depletion was confirmed in PC3.shCtBP1 xenografts by IHC and RT-qPCR 
compared to PC3.pGIPZ control tumors (Fig. 3D-S3C). 
 
CtBP1 modulates cell adhesion, cell cycle and steroid hormone response pathways 
Since only HFD fed animals inoculated with PC3.shCtBP1 cells showed tumor growth impairment, we 
next investigated the molecular pathways deregulated by CtBP1 depletion that might decrease tumor 
development in vivo. We performed a whole genome expression array (Affymetrix HuGene 1.0 ST) from 
PC3.shCtBP1 and PC3.pGIPZ tumor xenografts growing in HFD fed mice. These arrays interrogate 28,869 
annotated genes in the human genome. Three independent samples for each condition were used. Our 
results showed 823 genes differentially expressed (fold change > 1.5; p < 0.05) comparing PC3.pGIPZ 
with PC3.shCtBP1 xenografts from HFD fed mice. Functional gene ontology (GO) analysis revealed that 
most of these genes correspond to metabolic processes (44.1%), cell communication (30.7%) and cell 
adhesion (11.7%) among other biological functions (Fig 4A). 
Furthermore, Gene Set Enrichment Analysis (GSEA) revealed enhancement of genesets associated with 
cell cycle progression and proliferation (Supplementary Table 1). In addition, PC3.shCtBP1 samples 
showed enrichment of genesets associated with cell adhesion, hormone metabolism and BRCA1 targets 
gene regulation (Supplementary Table 2).  
 
CtBP1 depletion in xenografts from HFD fed mice induces E-cadherin related pathways. 
GSEA further allowed the identification of a large number of genes associated with cell adhesion 
genesets (Fig S4). Enrichment plot and heatmap from a selected cell adhesion geneset were shown. 
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Genes listed alongside heatmap were up-regulated in PC3.shCtBP1 compared to control PC3.pGIPZ 
tumors. Notably, a crucial cell adhesion gene over-represented in these genesets was CDH1 (E-cadherin) 
(Fig. 4B and S4). We validated this finding by RT-qPCR from tumor xenografts using CDH1 specific 
primers and found that CDH1 was overexpressed in PC3.shCtBP1 tumors (Fig S4B). IHC CDH1 analysis 
showed that PC3.shCtBP1 xenografts exhibited moderate to high E-cadherin staining at single cells, 
mainly at the cellular membrane of necrobiosis foci, while in PC3.pGIPZ tumors, E-cadherin staining was 
low to moderate, diffuse and located at single cells in necrobiosis foci (Fig 4C).  
 
CtBP1 depletion in xenografts from HFD fed mice induces aromatase related pathways. 
We found several steroid hormone metabolism related genes over-represented and over-expressed in 
PC3.shCtBP1 xenografts compared to control PC3.pGIPZ as indicated in heatmap and enrichment plots 
in Fig. 4D and S4C. From these analyses we found that one of the genes that was over-represented in 
the genesets related to hormone biosynthesis and metabolism was CYP19A1 (aromatase enzyme), 
involved in the estradiol synthesis by conversion from testosterone. We validated this finding by RT-
qPCR from tumor xenografts using specific primers for CYP19A1. As shown in Fig 4E, CYP19A1 
transcription was significantly induced in PC3.shCtBP1 compared to pGIPZ control.   
These results are consistent with the metabolic syndrome-like disease since HFD fed mice showed 
hormone imbalance. Nevertheless, the fact that CtBP1 depletion induces aromatase expression is a 
novel finding that reinforces the role of hormones and fat in tumor growth.  
 
CtBP1 depletion in xenografts from HFD fed mice decreases Cyclin D1 expression. 
PC3.pGIPZ xenografts also showed a marked enrichment of genesets related to cell cycle regulation and 
proliferation (Supplementary Table 1 and Fig. S5). Genes in these categories included several cyclin 
proteins (CCND1, CCND2 and CCND3) and BRCA1, among others. We focused our studies particularly on 
CCND1 (cyclin D1).  We validated the expression of this gene by RT-qPCR in tumors from HFD fed 
animals and we found that CCND1 is significantly diminished in PC3.shCtBP1 xenografts compared to 
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control (Fig. 5A). In addition, by IHC we found that PC3.pGIPZ tumors presented very high CCND1 
immunoreactivity, while CtBP1 depletion completely abolished CCND1 staining (Fig. 5B). 
 
CtBP1 and steroid hormones impair prostate tumor growth probably through BRCA1 regulation.  
It was previously reported that CtBP1 represses BRCA1 transcription in breast cancer cells (8). Here, we 
found by GSEA that PC3.shCtBP1 xenografts showed an enrichment of genes regulated by BRCA1 (Fig 
5C). Moreover, IHC analysis determined that CtBP1 depletion increased BRCA1 positive immunostaining 
compared to control xenografts from HFD fed animals (Fig. 5D).  
Based on several factors might be involved in BRCA1 transcription regulation in PCa, such as steroid 
hormones and CtBP1, we first determined BRCA1 transcription in the stable CtBP1 PC3 cell lines.  We 
found that CtBP1 repressed BRCA1 transcription in vitro, while CtBP1 depletion highly increased BRCA1 
expression compared to control PC3.pGIPZ cells (Fig. 6A). Then we exposed three PCa cell lines which 
differ in AR expression and androgen sensitivity to different testosterone concentrations. We found that 
BRCA1 mRNA levels significantly increased in PC3 cells exposed to testosterone, even after transfecting 
with the constitutive active AR vector (AR5) (Fig 6B). Similar results were found using 22Rv1 cells that 
express AR but are androgen insensitive (Fig.S6A). However, testosterone decreased BRCA1 mRNA levels 
in LNCaP cells (AR+/+ and androgen sensitive) (Fig. S6B).  
Moreover, by ChIP we determined that CtBP1 was associated to BRCA1 proximal promoter region, and 
testosterone released CtBP1 from this region (Fig. 6C). Altogether these results indicate that BRCA1 
transcription is regulated in PCa cell lines by CtBP1 and testosterone. 
It was previously reported that BRCA1 transcription is controlled by estradiol in breast cancer cell lines 
(8). To investigate whether BRCA1 transcription regulation in PCa is due to testosterone or estrogen, as 
a consequence of testosterone conversion to estradiol by the aromatase enzyme, we assessed BRCA1 
transcription in the presence of testosterone and an aromatase inhibitor (letrozole) that inhibits this 
conversion. We found that letrozole abolished BRCA1 induction by testosterone in both PC3 (Fig 6D) and 
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22Rv1 (Fig S6C) cells, however, letrozole have no effect over BRCA1 transcription in LNCaP cells exposed 
to testosterone (Fig. S6D). 
In summary, these observations indicate that BRCA1 transcription regulation by testosterone in PCa cells 
is modulated by aromatase-derived estrogen. Hence, CtBP1 and steroid hormone imbalance induced by 
the metabolic syndrome disease, govern BRCA1 transcription, which in turn, influence tumor 
suppression impeding prostate tumor growth. 
 
 
Discussion 
 
CtBP1 is a transcriptional co-repressor that binds to histone modifiers and recruits repressive complexes 
to tumor suppressor promoters in order to inhibit their expression. It is becoming increasingly clear that 
dysregulation of CtBP1 transcriptional repression plays a crucial role in tumorigenesis (4, 8, 12). We 
present new evidence for CtBP1-mediated oncogenesis in PCa. Our studies demonstrated that gene 
transcription regulation by CtBP1 provides an important molecular link among caloric intake, CtBP1 
function and tumor growth. We demonstrated that CtBP1 overexpression induces cell transformation 
and proliferation.  
We developed a metabolic syndrome-like disease in nude mice adding high fat content to their diet to 
modulate CtBP1 activity in a reduced NAD+/NADH ratio cellular context. These mice showed a clear 
hormone imbalance, hypercholesterolemia and histology alterations in their liver and kidneys. 
Surprisingly, CtBP1 knockdown delays tumor growth in these mice, suggesting that tumor growth in HFD 
fed animals is CtBP1-dependent.  
Several reports showed that HFD induced tumor growth in PCa xenografts using AR+/+ cell lines (22-25). 
Here, we found that HFD did not significantly influence tumor growth using the AR-/- cells (PC3) 
xenograft model. In addition, Wang et al. demonstrated that CtBP1 depletion decreased DU145 tumor 
growth in mice on normal chow diet (12). Here, CtBP1 depletion markedly diminished tumor growth 
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only in HFD fed mice. We believe that intratumor hormone and CtBP1 levels, and probably AR-cell status 
are crucial “collaborating” factors that are involved in PCa growth. 
 Takayama et al recently demonstrated that CtBP1 regulates AR signaling (26), showing that CtBP1 
exerts tumor suppressive effects in AR+/+ PCa cells. In contrast, Wang et al (12) described that CtBP1 is 
upregulated in metastatic PCa and  CtBP1 exerts growth stimulatory effects in tumor cells. We 
demonstrated here that testosterone downregulates CtBP1 mediated transcription targets in AR+/+ 
cells; meanwhile in AR-/- cells testosterone upregulates CtBP1 transcription targets.  We believe that 
one of the reasons for the inconsistency in CtBP1 functions may be due to impairments in the AR status 
in the different tumor cell lines. Further experiments will be necessary to understand the mechanism of 
regulation mediated by CtBP1 in AR-positive or AR-negative cells.  
Here, we found that CtBP1 represses BRCA1 transcription in PCa. We showed for the first time that 
testosterone regulates BRCA1 transcription, probably via its conversion to estrogen by the aromatase 
enzyme. The fact that several genesets for steroid hormone secretion and biosynthesis were enriched in 
CtBP1 depleted tumors in addition to an enhance aromatase expression is a novel finding that 
reinforced hormone and fat role in tumor growth. 
The role of NADH in regulating CtBP1 activity is also an important finding that increases researchers’ 
interest. CtBP1 has been proposed to act as a metabolic sensor, responding to changes in NADH levels 
and modulating gene expression (7). The combination of high NADH content in tumor cells and high fat 
rich diets are factors that might impact on carcinogenesis. Our work links reliably HFD and high NADH 
levels with CtBP1 dependent tumorigenesis. Even though, this novel molecular link, might be further 
explored to understand the potential implications of these pathways in PCa risk. 
Expression array profiles from these xenografts showed that the major biological processes affected by 
CtBP1 depletion are cell adhesion and communication, metabolism and cell cycle. Finally, we were able 
to determine the potential role of CtBP1 as a gene transcriptional regulator and its implication in tumor 
development in PCa. Both approaches, GSEA and in vivo xenograft model, allowed us to demonstrate 
that CtBP1 depletion dramatically decreased tumor growth and cell proliferation. Accordingly, Deng et al 
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generated CtBP1 transgenic mice (K5.CtBP1) that showed epidermis hyperproliferation by 
downregulation of p21 and BRCA1, and loss of E-cadherin expression (21).  
We also found that CtBP1 depletion had implication in regulation of genes involved in cell adhesion such 
as CDH1. However, other important players were also deregulated by CtBP1 depletion and still have to 
be studied, such as Integrin family (ITGB7, ITGAL, etc), cadherins (CDH3, CDH15, etc) and cell adhesion 
molecules (ICAM2, NCAM, CADM3, etc). Furthermore, we found several genes involved in cell 
communication and signaling also altered by CtBP1 depletion; probably having a great influence over 
PCa tumor signaling and growth.  
Obesity, type 2 diabetes and metabolic syndrome are placing an increasing burden on the healthcare 
systems. Many resources are currently being devoted to the identification of novel therapeutic targets 
that could alleviate or reverse the progress of these disorders. CtBP1 protein might be a critical target 
on these diseases. Recent studies have identified CtBP1 as a key transcriptional co-regulator in adipose 
tissue (27). CtBP proteins interact with several different partners to regulate the development of both 
white and brown adipocytes. Manipulation of CtBP1 function may provide a mechanism by which 
energy storage in white adipose tissue can be limited and energy expenditure by brown adipose tissue 
can be increased. 
Overall, our results reveal that CtBP1 govern crucial molecular pathways in prostate tumors in the 
presence of metabolic syndrome. Thus, it will be important to determine CtBP1 expression level status 
in the tumors from patients with metabolic syndrome to improve prognosis and disease management. 
In the future, it will be also important to correlate high fat consumption/weight gain/ body fat/BMI with 
CtBP1 expression to better understand this role. Finally, CtBP1 pathway might help to identify new 
molecular candidates for a better prediction of the disease outcome. 
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Legend to figures 
 
Figure 1. CtBP1 induces cell transformation and proliferation. (A) CtBP1 IHC for radical prostatectomies 
from different stages of PCa pathogenesis (normal gland to highly undifferentiated adenocarcinoma). An 
increment in positive immunostain was observed from normal to carcinomatous tissue. Similar positive 
nuclei stain in muscular and connective stromal fibers were seen in all tissues. Magnification 250x. (B) 
CtBP1 RT-qPCR from PCa cell lines. Fold induction was calculated normalizing data to Actin β and 
control. Bars represent the average and standard deviation of one representative experiment. ** p<0.01 
(C) Western blot, from PC3.CtBP1, PC3.shCtBP1 and PC3.pGIPZ stable cells using specific CtBP1 and Actin 
β antibodies. Quantification was obtained by normalization to Actin β as indicated under the bands. (D) 
Clonogenic assay from PC3.CtBP1, PC3.shCtBP1 and PC3.pGIPZ stable transfected cells. A representative 
photograph for each group, histograms for area distribution and colony number and area analyses are 
shown (boxes).  
 
Figure 2. HFD consumption for 16 weeks induced metabolic syndrome-like disease in mice. (A) Weekly 
average body weight from nu/nu mice fed with CD or HFD was plotted normalizing data to initial body 
weight. Box plots for (B) cholesterol and (C) total testosterone levels for CD or HFD fed mice are shown. 
Boxes represent the interquartile range, the horizontal line within each box represents the median, and 
the upper and lower whiskers represent the standard deviation of one independent experiment. 
**p<0.01  
 
Figure 3. CtBP1 depletion decreases tumor growth in HFD fed mice. Tumor growth curves from (A) CD 
or (B) HFD male nu/nu mice inoculated with PC3.pGIPZ or PC3.shCtBP1 cells after 12 weeks of diet. Each 
data point represents tumor volume average and standard deviation from each group of animals. (C) 
Tumors removed were used to determine NAD+/NADH ratio. Plotted boxes represent the interquartile 
range, the horizontal line within each of the boxes represents the median, and the upper and lower 
whiskers represent the standard deviation. * p < 0.05 (D) H&E and CtBP1 IHC staining from tumor 
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sections generated as xenografts in CD or HFD fed mice (Magnifications 250x). HFD PC3.shCtBP1 tumors 
showed irregular and hyperchromatic nuclei with several necrobiosis and leukocyte foci.  
 
Figure 4. Microarray analysis and functional genomics of xenografts. (A) Functional GO annotations 
from 823 genes differentially expressed in PC3.pGIPZ and PC3.shCtBP1 HFD xenografts using Panther 
software after Hugene 1.0 ST array hybridization and normalization. (B) GSEA from microarray data from 
HFD tumor xenografts. Enrichment plot and heatmap from a selected geneset were shown. Only genes 
that significantly contribute to core enrichment were shown in heatmap. (C) CDH1 (e-cadherin) IHC from 
PC3.pGIPZ and PC3.shCtBP1 xenografts HFD fed mice (Magnifications 400x). (D) GSEA from microarray 
data from HFD tumor xenografts showing enrichment plot and heatmap from steroid hormone 
biosynthesis. (E) RT-qPCR from the HFD fed mice tumors using specific primers for CYP19A1. Fold 
induction was calculated normalizing data to Actin β and control. Bars represent the average and 
standard deviation from 3 mice.  * p < 0.05 
 
Figure 5. Differentially expressed genes identified by whole genome expression array. (A) CCND1 RT-
qPCR from the HFD fed mice tumors. Fold induction was calculated normalizing data to Actin β and 
control. Bars represent the average and standard deviation from 3 mice. * p < 0.05  (B) CCND1 IHC from 
PC3.pGIPZ and PC3.shCtBP1 xenografts HFD fed mice (Magnifications 400x). (C) GSEA from microarray 
data from HFD tumor xenografts. BRCA1 targets enrichment plot and heatmap geneset were shown. 
Only genes included in the core enrichment were shown at heatmap. (D) BRCA1 IHC staining from tumor 
sections generated as xenografts in HFD fed mice (Magnifications 400x).  
 
Figure 6.  CtBP1 and testosterone regulates BRCA1 transcription. (A) BRCA1 RT-qPCR from PC3 stable 
cell lines. Fold induction was calculated normalizing data to Actin β and control PC3.pGIPZ cells. Bars 
represent the average and standard deviation of one representative experiment. (B) BRCA1 RT-qPCR 
from PC3 cells transiently transfected with pcDNA3 or AR5 expressing vectors, grew in charcoal FBS-
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medium and exposed to testosterone or vehicle for 24h. Fold induction was calculated normalizing data 
to Actin β and control. Bars represent the average and standard deviation of one representative 
experiment. (C) CtBP1 specific ChIP-scanning from PC3 cells incubated in charcoal FBS medium and 
exposed to testosterone or vehicle for 24hs. Specific primers scanning BRCA1 promoter at the indicated 
sites were used. Enrichment was calculated normalizing data to INPUT and non-specific IP antibody. (D) 
BRCA1 RT-qPCR from PC3 cells, grown as indicated above and pretreated with letrozole (1h) and then 
exposed to testosterone or vehicle (24h). Fold induction was calculated normalizing data to Actin β and 
control. Data represents the average and standard deviation of one representative experiment. * p < 
0.05; ** p < 0.01 
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